Figure 1.
Western Blot of MCT1 and MCT4.
In all cell lines investigated (A-549; lung adenocarcinoma, H661; large cell carcinoma, U-251 MG; neuronal glioblastoma) a protein band of approximately 40 kDa was detected corresponding to MCT1 and MCT4. Equal loading was ensured by B-actin.
Figure 2.
Immunhistochemical staining of MCT1–4 in NSCLC.
Low expression: A) MCT1, B) MCT2, C) MCT3, D) MCT4. High expression: E) MCT1, F) MCT2, G) MCT3, H) MCT4. 100× and 400× magnification.
Table 1.
Prognostic clinicopathologic variables as predictors of disease-specific survival in 335 NSCLC patients (univariate analyses; log-rank test).
Figure 3.
Kaplan Meier curves with DSS for expression of MCT1 and co-expression variables.
Kaplan Meier curves with disease-specific survival for expression of monocarboxylate transporter (MCT)1 in cancer cells and stromal cells and the co-expression variable GLUT1c+MCT4c and GLUT1c+MCT1s in NSCLC. A) MCT1 in cancer cells, B) MCT1 in stromal cells, C) GLUT1c+MCT4c, D) GLUT1c+MCT1s.
Table 2.
Monocarboxylate transporters (MCT) 1–4 in cancer and stromal cells as predictors of disease-specific survival in 335 NSCLC patients (univariate analyses; log-rank test).
Table 3.
Metabolic co-expression variables in cancer and stromal cells as predictors of disease-specific survival in 335 NSCLC patients (univariate analyses; log-rank test).
Table 4.
Results of Cox regression analyses (backward stepwise model) for clinicopathological factors and monocarboxylate transporters (MCTs) (model 1) and metabolic co-expression variables (*model 2).